- Shareholders re-elected all existing members of the Board of Directors who stood for re-election and elected Marion Helmes and Roger Nitsch as new members of the Board of Directors
- Albert M. Baehny was re-elected as Chairman of the Board of Directors for another year
- A dividend of CHF 3.00 per share will be paid out starting from 11 May 2022
- 33,179,173 shareholders delegated their votes to the independent proxy, representing 45% of the share capital
- Board of Directors to initiate audit tender in Q2 2022 for services starting from the financial year 2024
Today, Lonza Group Ltd hosted its Annual General Meeting (AGM), led by the Chairman of the Board of Directors, Albert M. Baehny. To ensure the continuing health and safety of Lonza’s shareholders and employees, the 2022 AGM was conducted without the presence of shareholders. Lonza had previously recommended that shareholders delegate their votes to the independent proxy on 24 March 2022. The independent proxy represented 100% of the 33,179,173 votes represented at the AGM.
The Board members standing for re-election (Albert M. Baehny, Angelica Kohlmann, Christoph Mäder, Barbara Richmond, Jürgen Steinemann and Olivier Verscheure) were all elected for a further term in office of one year. Werner Bauer and Dorothée Deuring did not stand for re-election.
The Annual General Meeting re-elected Albert M. Baehny as Chairman of the Board of Directors for a term in office of one year. The shareholders also elected Marion Helmes and Roger Nitsch as new members of the Board, and confirmed Angelica Kohlmann, Christoph Mäder and Jürgen Steinemann as the three members of the Nomination and Compensation Committee for a further term in office of one year.
The shareholders supported all other motions proposed by the Board of Directors, including among others the acceptance of the remuneration report and the binding votes on the compensation for the Board of Directors and the Executive Committee.
A dividend of CHF 3.00 per share, as proposed by the Board of Directors and accepted by the shareholders, will be paid out starting from 11 May 2022. Fifty percent of this dividend will be paid out of the capital contribution reserve and will be free from Swiss withholding tax.
For further information please see the short-form minutes of the 2022 Lonza Annual General Meeting under the following link.
In addition, the Board of Directors of the Lonza Group has decided to initiate in Q2 2022 a tender for the audit and related services of the Group and its subsidiaries starting from the financial year 2024.
The overall objective of the audit tender is to select the best auditor in terms of quality within a competitive price range through a non-discriminatory, transparent and robust selection process. Potential participant firms should have sufficient expertise, experience, IT capabilities and geographical footprint to audit a listed company with a global scale and high complexity of operations. The tender is open to any audit firm meeting the above requirements. Please contact Lonza_audit_tender_2022@lonza.com by May 15, 2022 in case your firm would like to participate.
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.
Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare industry.
Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 16,000 employees (full-time equivalent), we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 5.4 billion with a CORE EBITDA of CHF 1.7 billion in Full-Year 2021. Find out more at www.lonza.com
Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter
Lonza Group Ltd.
Münchensteinerstraße 38
CH4002 Basel
Telefon: +41 (61) 3168638
Telefax: +41 (61) 3169638
http://www.lonza.com
Head of Corporate Communications
Telefon: +41 (79) 599-6260
E-Mail: victoria.morgan@lonza.com
Telefon: +41 (61) 316-8540
Fax: +41 (61) 316-9540
E-Mail: dirk.oehlers@lonza.com